SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent achievements, upcoming events and chief financial officer transition plan. “We continue to focus on executing our Phase 3 program studying AG10 in patients with transthyretin (TTR) amyloidosis (ATTR)....